Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan · Delayed Price · Currency is TWD 82.30
+0.20 (0.24%)
Sep 4, 2025, 2:57 PM CST
Handa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,338 | 830.67 | 1,106 | 197.68 | 29.24 | 28.86 | Upgrade | |
Revenue Growth (YoY) | 37.47% | -24.92% | 459.66% | 576.16% | 1.30% | -65.67% | Upgrade |
Cost of Revenue | 124.97 | 1.17 | 1.3 | 18.71 | 1.46 | 1.42 | Upgrade |
Gross Profit | 1,213 | 829.5 | 1,105 | 178.97 | 27.77 | 27.44 | Upgrade |
Selling, General & Admin | 140.9 | 119.54 | 144.25 | 87.31 | 72.67 | 70.87 | Upgrade |
Research & Development | 298.65 | 291.91 | 267.34 | 179.78 | 208.99 | 274.04 | Upgrade |
Operating Expenses | 439.55 | 411.44 | 411.59 | 267.09 | 281.66 | 344.92 | Upgrade |
Operating Income | 773.05 | 418.06 | 693.43 | -88.12 | -253.88 | -317.48 | Upgrade |
Interest Expense | -0.83 | -0.49 | -0.22 | -0.28 | -0.23 | -0.45 | Upgrade |
Interest & Investment Income | 51.06 | 57.06 | 18.16 | 0.5 | 0.29 | 2.99 | Upgrade |
Earnings From Equity Investments | -4.62 | -1.81 | 2.37 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 26.9 | 26.9 | 1.71 | 44.02 | -7.27 | -14.31 | Upgrade |
Other Non Operating Income (Expenses) | -160.71 | -20.36 | 0.03 | 0.73 | 0.27 | 13.3 | Upgrade |
EBT Excluding Unusual Items | 684.85 | 479.36 | 715.47 | -43.15 | -260.82 | -315.95 | Upgrade |
Gain (Loss) on Sale of Assets | -0.19 | -0.19 | 4.61 | -0 | 0.02 | -0 | Upgrade |
Asset Writedown | - | - | - | - | - | -4.5 | Upgrade |
Legal Settlements | - | - | 72.41 | - | - | - | Upgrade |
Pretax Income | 684.67 | 479.17 | 792.49 | -43.15 | -260.8 | -320.45 | Upgrade |
Income Tax Expense | 63.97 | 6.43 | 65.6 | -3.14 | -13.13 | -38.34 | Upgrade |
Net Income | 620.7 | 472.74 | 726.89 | -40.01 | -247.67 | -282.1 | Upgrade |
Net Income to Common | 620.7 | 472.74 | 726.89 | -40.01 | -247.67 | -282.1 | Upgrade |
Net Income Growth | 37.23% | -34.96% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 146 | 140 | 134 | 126 | 118 | 116 | Upgrade |
Shares Outstanding (Diluted) | 147 | 141 | 135 | 126 | 118 | 116 | Upgrade |
Shares Change (YoY) | 4.96% | 4.73% | 7.29% | 6.65% | 1.87% | 5.35% | Upgrade |
EPS (Basic) | 4.25 | 3.37 | 5.41 | -0.32 | -2.10 | -2.44 | Upgrade |
EPS (Diluted) | 4.23 | 3.35 | 5.40 | -0.32 | -2.10 | -2.44 | Upgrade |
EPS Growth | 30.54% | -37.96% | - | - | - | - | Upgrade |
Free Cash Flow | 236.66 | 489.84 | 667.42 | -212.21 | -184.82 | -315.88 | Upgrade |
Free Cash Flow Per Share | 1.61 | 3.47 | 4.95 | -1.69 | -1.57 | -2.73 | Upgrade |
Dividend Per Share | 1.500 | 1.500 | 1.000 | - | - | - | Upgrade |
Dividend Growth | 50.00% | 50.00% | - | - | - | - | Upgrade |
Gross Margin | 90.66% | 99.86% | 99.88% | 90.53% | 95.00% | 95.07% | Upgrade |
Operating Margin | 57.79% | 50.33% | 62.68% | -44.58% | -868.42% | -1100.10% | Upgrade |
Profit Margin | 46.41% | 56.91% | 65.70% | -20.24% | -847.17% | -977.52% | Upgrade |
Free Cash Flow Margin | 17.69% | 58.97% | 60.33% | -107.35% | -632.19% | -1094.57% | Upgrade |
EBITDA | 854.78 | 421.12 | 698.48 | -81.3 | -245.05 | -309.06 | Upgrade |
EBITDA Margin | 63.91% | 50.70% | 63.14% | -41.13% | - | - | Upgrade |
D&A For EBITDA | 81.73 | 3.06 | 5.06 | 6.82 | 8.83 | 8.42 | Upgrade |
EBIT | 773.05 | 418.06 | 693.43 | -88.12 | -253.88 | -317.48 | Upgrade |
EBIT Margin | 57.79% | 50.33% | 62.68% | -44.58% | - | - | Upgrade |
Effective Tax Rate | 9.34% | 1.34% | 8.28% | - | - | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.